ARS Pharmaceuticals Inc (SPRY)
13.38
-0.17
(-1.25%)
USD |
NASDAQ |
Nov 21, 16:00
13.39
+0.01
(+0.07%)
After-Hours: 20:00
ARS Pharmaceuticals Debt to Equity Ratio: 0.00 for Sept. 30, 2024
Debt to Equity Ratio Chart
Historical Debt to Equity Ratio Data
| Date | Value |
|---|---|
| September 30, 2024 | 0.00 |
| June 30, 2024 | 0.00 |
| March 31, 2024 | 0.00 |
| December 31, 2023 | 0.00 |
| September 30, 2023 | 0.00 |
| Date | Value |
|---|---|
| June 30, 2023 | 0.00 |
| March 31, 2023 | 0.00 |
| December 31, 2022 | 0.00 |
| September 30, 2022 | |
| June 30, 2022 | -0.1516 |
Debt to Equity Ratio Definition
The debt to equity ratio measures the (Long Term Debt + Current Portion of Long Term Debt) / Total Shareholders' Equity. This metric is useful when analyzing the health of a company's balance sheet.
Debt to Equity Ratio Range, Past 5 Years
-0.1516
Minimum
Jun 2022
--
Maximum
Dec 2022
-0.0168
Average
--
Median
Dec 2022
Debt to Equity Ratio Benchmarks
| Exelixis Inc | 0.00 |
| Assembly Biosciences Inc | 0.00 |
| Protagonist Therapeutics Inc | 0.00 |
| Precision BioSciences Inc | 0.3434 |
| Avidity Biosciences Inc | 0.00 |
Debt to Equity Ratio Related Metrics
| Total Assets (Quarterly) | 217.60M |
| Total Liabilities (Quarterly) | 16.62M |
| Shareholders Equity (Quarterly) | 200.98M |
| Current Ratio | 12.56 |